{
  "abstract": "Health systems are rapidly adopting artificial intelligence (AI), with 2 in 3 physicians now using it for tasks like chart summaries and diagnoses—a 78% increase since 2023.1 Yet most clinical AI tools face limited US Food and Drug Administration (FDA) oversight, leading to inadequate evaluation.2 Over half of 1000 FDA-authorised AI devices reported no performance metrics and nearly half documented no clinical studies.3 Unlike pharmaceuticals, which require randomised trials and rigorous surveillance, AI tools are being deployed without comparable standards.",
  "authors": [
    {
      "affiliations": [
        "Stanford University School of Medicine, Stanford, California, USA"
      ],
      "name": "Bhav Jain"
    },
    {
      "affiliations": [
        "Qualified Health, Palo Alto, California, USA"
      ],
      "name": "Aman Sinha"
    },
    {
      "affiliations": [
        "Qualified Health, Palo Alto, California, USA"
      ],
      "name": "Nicholas Chedid"
    },
    {
      "affiliations": [
        "Qualified Health, Palo Alto, California, USA",
        "Institute for Healthcare Improvement, Boston, Massachusetts, USA"
      ],
      "name": "Kedar Mate"
    }
  ],
  "title": "Why health AI needs protocols, not just pilots",
  "uid": "256f7252-fca3-57e3-a357-908254637936"
}